The rational of intra-articular viscosupplementation is based on both the biological and mechanical properties of HA, which exerts positive effects on the modulation of the entire joint environment. The aim of the present double blind controlled study was to evaluate the effects in terms of pain control and functional recovery provided by a single intra-operative injection of HA performed at the end of arthroscopic partial meniscectomy. Patients included in this trial were randomized in two treatment groups: the first one received a single injection of HA (Hymovis 24 mg/3ml, Fidia Farmaceutici Spa, Padova, Italy) at the end of the arthroscopic meniscectomy, whereas the second group was treated by surgery alone. All patients were evaluated basally, at 15, 30, 60, and 180 days after surgery by the following evaluation tools: IKDC (International Knee Documentation Committee) subjective, VAS (Visual Analogue Score) for pain, EQ-VAS for general Health Status, KOOS (Knee Injury and Osteoarthritis Outcome Score) and Tegner score. Furthermore, during the basal evaluation and at each follow-up visit up to 2 months, active and passive Range of Motion (ROM) of both the operated and contralateral knee were documented; also in addition, the trans-patellar circumference of both knees was registered to assess the trend of knee swelling over time.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
90
A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
The patients randomized in this group will receive arthroscopic meniscectomy alone
II Orthopaedic Clinic, Rizzoli Orthopaedic Institute
Bologna, Emilia-Romagna, Italy
Change in IKDC (International Knee Documentation Committee) score
Time frame: basal, 15,30,60,180 days
Change in KOOS (Knee Injury and Osteoarthritis Outcome Score)
Time frame: basal, 15,30,60,180 days
Change in Tegner Score
Time frame: basal, 15,30,60,180 days
Change in VAS (Visual Analogue Scale) for pain
Time frame: basal, 15,30,60,180 days
Change in EQ-VAS for general health
Time frame: basal, 15,30,60,180 days
Change in transpatellar circumference over time
Time frame: basal, 15,30,60,180 days
Change in active and passive ROM
Time frame: basal, 15,30,60,180 days
Adverse events report
Time frame: 15 days
Adverse events report
Time frame: 30 days
Adverse events report
Time frame: 60 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.